PACS Group, Inc. (PACS) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and nine months ended September 30, 2025. PACS Group, Inc. is a leading post-acute healthcare company operating 320 skilled nursing, assisted living, and independent living facilities across 17 states. As of the reporting date, the company operated 32,677 skilled nursing beds and 2,525 assisted living beds. The company operates as a holding company with independent operating subsidiaries.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 30, 2025 | 9 Months Ended Sept 30, 2025 |
|---|---|---|
| Total Revenue | $1,344,567 | $3,930,953 |
| Net Income | $52,330 | $131,676 |
| Net Income Attributable to PACS | $52,406 | $131,841 |
| Diluted EPS | $0.32 | $0.80 |
| Operating Cash Flow (9 Months) | N/A | $407,614 |
| Cash and Cash Equivalents | $355,672 | $355,672 |
| Total Debt (Current + Long-Term) | $253,377 | $253,377 |
| Line of Credit Outstanding | $100,000 | $100,000 |
Note: Total Debt includes $7,474 in current maturities and $245,903 in long-term debt (net of deferred financing fees), plus the $100,000 line of credit balance.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31.0% year-over-year for the quarter and 36.4% for the nine-month period, driven primarily by a 19.0% increase in operational beds and a 22.7% increase in patient days.
- Profitability: Net income surged 222.8% for the quarter and 587.5% for the nine-month period compared to the prior year. Operating income increased 275.7% for the quarter.
- Expense Increases: Cost of services rose 23.1% (quarter) and 31.7% (nine months), largely due to increased salaries and wages from new facilities. General and administrative expenses increased 45.3% (quarter) and 18.7% (nine months), significantly impacted by legal fees associated with ongoing investigations.
- Occupancy: Combined occupancy rates decreased slightly to 89.0% for the quarter and 88.9% for the nine months, primarily due to lower occupancy in "New" and "Ramping" facility cohorts, offset by stable performance in "Mature" facilities (94.8% and 95.0% respectively).
Guidance, Risks, and Contingencies
Management Commentary & Outlook: Management expects to continue using the Amended and Restated Credit Facility for acquisitions and working capital, subject to resolving current forbearance terms. The company believes current cash balances and operating cash flows are sufficient for the next 12 months.
Credit Facility Status: The company is currently in a forbearance agreement with its lenders (extended through November 30, 2025) regarding "Technical Events of Default." During this period, the company is prohibited from borrowing new loans and must maintain a minimum liquidity of $100 million. The company is in active discussions to amend the facility.
Legal and Regulatory Risks:
- DOJ Investigations: Multiple ongoing investigations by the U.S. Department of Justice regarding potential False Claims Act violations, including improper patient referrals, billing practices under the Patient-Driven Payment Model (PDPM), and 1135 COVID Waiver practices.
- SEC Investigation: The SEC is investigating the company's accounting, financial reporting, and internal controls.
- Securities Litigation: A consolidated securities class action (Manchin v. PACS Group, Inc.) and shareholder derivative actions allege a scheme to inflate revenue and profitability. These actions are currently stayed pending the resolution of motions to dismiss.
Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in the control environment and revenue recognition processes. A remediation plan is underway, including the hiring of an Interim Chief Compliance Officer.
Investor Verification Checklist
- Forbearance Resolution: Verify the status of negotiations with lenders to exit the forbearance agreement and restore full borrowing capacity before the November 30, 2025 deadline.
- Investigation Outcomes: Monitor developments in the DOJ and SEC investigations, as well as the securities class action, for potential fines, penalties, or restatements.
- Internal Control Remediation: Assess the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
- Occupancy Trends: Track occupancy rates in "New" and "Ramping" facilities to ensure they improve as they mature, supporting revenue growth.
- Liquidity Position: Confirm the company maintains the required $100 million unrestricted cash balance during the forbearance period.